Reply to thread

Message: [QUOTE="Munyaradzi Mafaro, post: 52311, member: 636"] University of Nairobi researchers presented findings from three HIV treatment studies at the International AIDS Society Conference in Rwanda. The investigations examined how standard antiretroviral therapy affects adults over 60 across Africa. Scientists discovered that conventional HIV medications might damage bone and kidney function in elderly patients. The research team evaluated whether alternative treatments could provide safer care for aging populations. Dr. Loice Ombajo from the Centre for Epidemiological Modelling and Analysis emphasized that older HIV patients represent a neglected demographic. The primary study enrolled 520 participants aged 60 and above who had received antiretroviral treatment for over a decade. Researchers randomly assigned patients to continue standard TLD therapy or switch to B/F/TAF combination treatment. Results after 96 weeks demonstrated that B/F/TAF maintained viral suppression while improving bone and kidney health markers. The medication shortage created ethical dilemmas when the study concluded. Follow-up investigations examined simplified dual therapy regimens and tracked long-term health outcomes. The Sungura trial tested whether two-drug combinations could match three-drug effectiveness in elderly patients. Preliminary results showed no treatment failures or patient withdrawals after 24 weeks. The ongoing Twiga study compares health trajectories between HIV-positive and HIV-negative seniors. Early data revealed that HIV patients experienced more chronic conditions and organ damage than their uninfected counterparts. [/QUOTE]

Name